GlassScriptPhysician profile
Melissa Babcock
NPI 1700800752
$3,208.48
in general payments reported to CMS, 2019-2025
29 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $203 · 2021: $681 · 2022: $317 · 2023: $578 · 2024: $501 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.60 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $918.33 | 2019-2025 | |
| Abbvie INC. | $662.61 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $262.87 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $159.36 | 2023-2025 | |
| Genzyme Corporation | $154.10 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $142.71 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $120.94 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Amgen INC. | $99.14 | 2022-2025 | Otezla |
| Pfizer INC. | $85.32 | 2019-2025 | |
| Leo Pharma INC. | $68.18 | 2022 | |
| Arcutis Biotherapeutics, INC. | $66.41 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $54.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $43.30 | 2021 | |
| Mayne Pharma Commercial LLC | $40.05 | 2021-2025 | |
| Genentech USA, INC. | $35.02 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $32.80 | 2021-2025 | Bimzelx |
| Organogenesis INC. | $30.79 | 2023 | Puraply |
| Teva Pharmaceuticals USA, INC. | $25.28 | 2024 | Simlandi |
| Dermavant Sciences, INC. | $23.98 | 2024 | Vtama |
| Verrica Pharmaceuticals INC. | $23.58 | 2023 | Ycanth |
| Boston Scientific Corporation | $22.94 | 2025 | General - Pain Management |
| Kyowa Kirin, INC. | $22.89 | 2025 | |
| Biofrontera INC. | $22.26 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.13 | 2020 | |
| Incyte Corporation | $16.53 | 2025 | Opzelura |
| Organon LLC | $16.38 | 2025 | Vtama |
| Botanix Sb INC | $15.58 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $12.62 | 2022 | |
| Kerecis Limited | $11.84 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Babcock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.